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Abstract 
During the perinatal period, lungs undergo changes to adapt to air breathing. The genes 
involved in these changes are developmentally regulated by various signaling pathways, 
including the cyclic nucleotide cAMP. As PDE4s are critical enzymes for regulation of cAMP 
levels, the objective of this study was to investigate PDE4s ontogeny in developing rat lung 
during the perinatal period. Pulmonary PDE4 activity, PDE4A-D and PDE4B and PDE4D 
variants expression levels, PDE4B and PDE4D protein levels, and PDE4Ds localization in 
distal lung were determined. PDE4 activity increased towards term, dropped at birth, and 
increased thereafter to reach a plateau at the end of the second week of life. PDE4B2 and 
PDE4D long forms demonstrated a pattern of expression that increased markedly at birth. 
After birth, PDE4D were expressed in alveolar epithelial and mesenchymal cells. The study 
therefore evidenced striking variations in expression patterns among the PDE4 family that 
differed from changes in global PDE4 activity. 
 
Key words: lung development, phosphodiesterases 4, cyclic AMP 
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Introduction 
Successful transition to air breathing at birth involves dramatic changes in lung 
physiology, including differentiation of alveolar type II cells, clearance of pulmonary fluid, 
decrease of pulmonary vascular resistance, and surfactant release (Cardoso, 2001). Defects in 
these physiological changes may affect neonates and can be responsible for neonatal 
respiratory disorders, which represent the leading cause of hospitalization in neonatal 
intensive care units. Preterm infants may develop bronchopulmonary dysplasia (BPD), a 
disease mainly related to impairment of alveolarization and microvascular development. 
Identification of the molecular and physiological processes controlling perinatal lung 
development and alveolarization would be promising to explore and develop new therapeutic 
approaches to cure or prevent respiratory disorders. 
 Lung adaptation to air breathing and lung development are controlled by a large number 
of factors. Many of these factors involve signaling pathways involving cAMP (Mendelson, 
2000). Earlier studies have focused on developmental changes in cAMP/PKA pathway as key 
controllers of the actions of catecholamines or other hormones in perinatal lungs. 
Manipulation of the cAMP pathway facilitated surfactant release and reduced surface tension 
in experimental models (Aeberhard et al., 1984; Odom et al., 1987; Fisher et al., 1991). 
Ontogenic variations in PKA and some of its protein substrates have been described: the 
phosphorylation pattern and the expression of specific phosphatase or adenylate cyclase 
activities changed during lung development (Whitsett et al., 1982a; Whitsett et al., 1982b; 
Whitsett et al., 1983; Whitsett et al., 1985; Acarregui et al., 1998).  
Cyclic nucleotide phosphodiesterases (PDE) represent a superfamily of enzymes that 
hydrolyze cAMP. Eleven families of PDE have been described in mammals, and selective 
inhibitors of specific families are now used or proposed to treat various disorders including 
cardiovascular disease, erectile dysfunction, pulmonary arterial hypertension, and chronic 
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pulmonary disorders (Bender and Beavo, 2006). Among these families, the PDE4 family has 
been extensively investigated over recent decades for its potential as a new pharmacological 
target in asthma and chronic obstructive pulmonary disease in adults (Boswell-Smith and 
Spina, 2007; Spina, 2008).  
PDE4s are encoded by four genes designated A through D, and encompass more than 
20 different proteins produced through differential promoter activation (Conti et al., 2003). 
Because of this diversity, each PDE4 protein is now thought to have a specific, non-redundant 
function in controlling cAMP metabolism within physiological processes (Conti et al., 2003). 
The ontogeny and precise role of PDE4s in the perinatal developing lung and alveolarization 
have not yet been investigated. 
Rat pups are a common experimental model to study normal or pathological distal 
lung development. They are born at the saccular phase of lung development and 
alveolarization is an entirely postnatal event, starting on the fourth postnatal day and ending at 
day 21. The potential of PDE4 inhibition was evaluated in an experimental model of BPD in 
rat pups and demonstrated that PDE4 inhibition may impair alveolarization (Mehats et al., 
2008). Although a global impact via a decrease of somatic growth is certainly involved in this 
deleterious effect, the possibility of a specific involvement of PDE4 proteins in lung 
development must also be considered.  
The present study investigated global PDE4 activity and specific PDE4 protein 
expression patterns in fetal and newborn rats. Specific isoforms of PDE4B and PDE4D varied 
profoundly during distal lung development, suggesting a role for these proteins in perinatal 
lung physiology. 
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Results 
PDE4 activity in lung during fetal and early postnatal life 
At fetal day 17 (F17, term F22), PDE4 activity was 14±2 pmol/min/mg and increased 
significantly towards term, doubling at F21 (28±3 pmol/min/mg) (Figure 1). After birth, 
PDE4 activity decreased transiently (16±2 pmol/min/mg) before increasing sharply from P7 
(44±7 pmol/min/mg), reaching a plateau at P14 (60±9 pmol/min/mg). No gender effect was 
observed (at P1 males: 18±1 pmol/min/mg, n=5; females: 17±4 pmol/min/mg, n=6; other data 
not shown). 
  
Pulmonary PDE4 mRNA levels during fetal and early postnatal life  
Developmental changes in mRNA levels of the four PDE4 genes were investigated 
using generic primers covering all known variants derived from each gene. Data are expressed 
as Ct, which means that a variation of 1 cycle represents a 2-fold increase or decrease and 
that a low Ct indicates high expression. At F17, PDE4A and PDE4B mRNAs were the most 
abundant forms, with 8-fold lower and 1,000-fold lower expression of PDE4D and PDE4C, 
respectively (Table 2). PDE4C remained the PDE4 with the lowest expression at all stages 
examined, although PDE4C mRNA increased significantly after F21 (Figure 2). PDE4A 
mRNA expression levels did not change significantly either during saccular and alveolar 
stages, or at birth. PDE4B and PDE4D mRNAs rose at F21, peaked on P1 to reach 25- and 
60-fold their F17 levels, respectively, then decreased 2- to 3-fold at the beginning of 
alveolarization and decreased further at P21 (Figure 2). 
 
PDE4B and PDE4D protein levels in developing rat lung 
Subsequent studies focused on PDE4B and PDE4D variant protein expression. Using 
PDE4B-specific antibodies that recognized the common C-terminus of all PDE4B isoforms, a 
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single immunoreactive signal was observed with an apparent molecular mass of 71 kDa 
(Figure 3). The signal was faint at F17 and F19, increased slightly at F21 and was strong from 
P1 to P21. Using PDE4D-specific antibodies that recognized the common C-terminus of all 
PDE4D isoforms, four immunoreactive signals of 110, 105, 100, and 90-kDa, respectively, 
were detected with a differential pattern of expression during the developmental stages of the 
lungs. While the 110 kDa signal decreased and was faint after birth, 105 and 100 kDa signals 
were both more intense around P1 and P3, and the 90 kDa signal was mainly observed after 
birth. Immunoreactive bands of short-form PDE4D variants were not detected in any of the 
developmental stages investigated.  
 
PDE4B2 and long-form PDE4D mRNA levels in lung during fetal and early postnatal 
life 
Real-time PCR showed that PDE4B2 mRNA expression followed the same pattern as 
that of PDE4B detected with generic primers (Table 2). Among PDE4D long-form variants, 
PDE4D9 was the most abundant at F17, followed by PDE4D8, PDE4D3, PDE4D5, PDE4D4, 
and PDE4D7, and the most abundant form was expressed 15- to 16-fold higher than the least 
abundant form.  
PDE4D3 mRNA levels increased 8-fold at birth and decreased at P7 (Figure 4 and 
Table 2). PDE4D4 mRNA fell sharply after F17, representing a 1,000-fold decrease, and 
remained low during all of the following stages of development. PDE4D5 increased sharply at 
birth, reaching 8-fold the F17 levels, and subsequently decreased to a level not statistically 
different from that observed at F17. PDE4D7 and PDE4D8 mRNA levels increased 15- and 7-
fold respectively from F17 to F21. Their levels remained high from F21 to P7 with a peak at 
P1 for PDE4D8. PDE4D9 mRNA levels increased 6-fold at birth as compared to F17 and 
decreased thereafter. 
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PDE4Ds localization during distal lung development 
Antibodies directed against PDE4B were not suitable for immunohistochemical 
assessment of their localization in the distal developing lung.  
PDE4Ds were present at all stages of lung development investigated (F20, P1, P4, and 
P14)  Before birth, immunolabeling was punctate and ubiquitous with no evidence of 
expression specificity in epithelial or mesenchymal cells (Figure 5); no pro-SP-C signal was 
detected at this stage. Labeling was the strongest at P1 when PDE4D proteins were mainly 
localized in the alveolar wall in thin, elongated cells with the morphologic appearance of 
alveolar type I cells  as well as in mesenchymal cells. A few cells that stained for pro-SP-C, 
therefore likely to be alveolar type II cells, displayed some stains for PDE4D (Figure 6). At 
P4 and P14, the signal was very weak and mostly elongated (data not shown).. 
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Discussion 
The present study investigated the ontogeny of members of the PDE4 family during 
perinatal lung development in rat pups. Global PDE4 activity varied considerably during this 
period. This variation was associated with changes of the expression patterns of mostly 
PDE4B and PDE4D genes. In particular, PDE4D displayed a complex pattern with several 
isoforms being expressed at different phases of development. Immunofluorescence study of 
their localization in the distal lung suggested predominant expression in the walls of the 
alveoli with the most robust signal detected just after birth. 
Previous studies have described changes in cAMP levels and protein kinase (PKA) 
activity during rat lung perinatal development (Whitsett et al., 1983; Acarregui et al., 1998). 
The only way to inactivate cAMP within cells is via hydrolysis by PDE, and among the 11 
families of PDEs, PDE4 is thought to play a key role by modulating cAMP levels for many 
physiological events. The present study showed that global PDE4 activity increased towards 
the term of gestation, dropped at birth, then increased sharply to reach the highest level at the 
end of alveolarization. Global PDE4 activity in whole lung homogenates is the sum of the 
activities of several isoforms expressed from four genes, and only accounts for the total 
capacity of PDE4 enzymes to hydrolyze cAMP under the particular experimental conditions 
used and in the absence of external stimulation. However these variations of capacity to 
hydrolyze cAMP at time of key processes in lung development strongly suggest a role for 
PDE4s in both the preparation for air breathing and alveolarization. 
It has been postulated that genes that regulate these processes should be differentially 
expressed during strictly defined period of times during perinatal life (Boucherat et al., 2007). 
Strategies based on longitudinal evaluation of gene expression in this period have identified 
significant changes in the expression of several genes involved in these processes (Clerch et 
al., 2004; Foster et al., 2006; Boucherat et al., 2007). This strategy was applied to the PDE4 
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family by measuring steady-state levels of mRNAs for the four PDE4 genes, PDE4A-D, by 
real-time PCR. Because each gene expressed more than one variant, PDE4 mRNAs were 
initially examined by using generic primers allowing simultaneous amplification of all 
products of a particular gene. PDE4A mRNA steady-state levels were the highest among the 
various PDE4 in whole lung, and did not vary throughout the period investigated. PDE4C 
mRNA steady-state levels were the lowest of all PDE4 genes. Although PDE4C expression 
gradually increased during the first three weeks of life, this expression remained about 1,000-
fold lower than that of the other PDE4 genes at the end of alveolarization, suggesting that this 
gene did not play a major role in perinatal distal lung development. As measurements 
performed with whole lung tissue may hide strictly regulated expression in a few subsets of 
specialized cells, a role for these genes in perinatal lung development cannot be strictly 
excluded, but given the limited knowledge about the organization of the PDE4A and PDE4C 
variants and the absence of suitable biochemical tools to study them, the expression of these 
two genes was not investigated further. 
Steady-state levels of PDE4B and PDE4D mRNAs presented the same pattern of 
expression: increasing just before birth, reaching levels at birth almost 30- to 60-fold higher 
than the levels at day 17 of fetal life, respectively, and slowly decreasing towards the end of 
alveolarization. This pattern infers global regulation of PDE4B and PDE4D expression during 
the perinatal period and suggests a role in lung development, especially shortly after birth. 
Western blot analysis of PDE4B and PDE4D expression was performed to provide further 
information on the expression of these two genes. Although some variants displayed similar 
migration on SDS-PAGE, this criterion allowed us to first circumvent some specific variants 
of these genes. Only one immunosignal was detected for the PDE4B gene with an apparent 
molecular weight of 71 kDa, which may correspond to the PDE4B2 variant, the only variant 
currently described to present this migration pattern in the rat (Iona et al., 1998). Real-time 
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PCR measurements of PDE4B2 mRNA steady-state demonstrated an expression pattern 
similar to that obtained with generic pattern of PDE4B, implying that only PDE4B2 is 
expressed in the developing lung. The signal of this variant increased markedly from birth in 
terms of both mRNA and protein and remained strong at the protein level throughout the 
postnatal period, suggesting a role in adaptation to air breathing. PDE4B2 is expressed in 
several tissues with high expression in inflammatory cells (Wang et al., 1999). The invasion 
of macrophages into airspaces shortly after birth (van Rees et al., 1991) might account for this 
increase on the 1
st
 day of life but PDE4B2 expression may also be expressed in developing 
lung structures. Unfortunately, PDE4B antibodies available at the time of the study were not 
suitable to further localize this protein within distal lung (data not shown).  
The expression pattern of PDE4D was much more complex during the perinatal 
period. Four apparent signals above 90 kDa were observed in western blots that might 
represent the six long forms of PDE4D described to date, namely PDE4D3, PDED4, 
PDE4D5, PDE4D7, PDE4D8, and PDE4D9. According to the migration size of recombinant 
PDE4 in SDS-PAGE and the expression pattern of the mRNAs, the 110 kDa signal may be 
PDE4D4, the 90 kDa signals may be PDE4D3, PDE4D8, and PDE4D9, and the 100 and 105 
kDa signals may be PDE4D5 and PDE4D7. Accordingly, the pattern of expression of these 
proteins reflected the pattern of expression of their respective mRNAs detected by 
quantitative PCR : PDE4D4 expression fell at P21, PDE4D3 (90 kDa), PDE4D5 (100 kDa), 
PDE4D8 (90 kDa), and PDE4D9 (90kDa) had a peak of expression at birth, that, however, 
dropped at P7 but remained significantly different from the expression at F20, at the exception 
of PDE4D5 expression. PDE4D4, PDE4D7, and PDE4D8 are selectively transcribed in a 
limited number of tissues, while PDE4D3, PDE4D5, and PDE4D9 are present in most tissues 
(Richter et al., 2005). PDE4D4 was absent in adult rat lung, consistent with its absence at the 
end of alveolarization. The fact that its expression was highest and fell sharply after F17 
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suggested a role in late fetal development. The increase of PDE4D7 and PDE4D8 mRNAs 
just before birth and the relative stability of their expression during the alveolarization period, 
as well as their restricted expression within the organism suggest a more specific role in distal 
lung development. The relatively wide expression of PDE4D3, PDE4D5, and PDE4D9 within 
the organism infers they have a role in ubiquitous functional pathways shared by several 
tissues. These isoforms show a peak of expression at birth. Given the role of PDE4 in 
hormonal pathways (Mehats et al., 2002), one may speculate that at birth, hormonal 
regulations of postnatal lung physiology begin to be tightly regulated by selective PDE4s. 
Notably, clearance of fetal lung fluid is initiated secondary to beta-adrenergic-stimulated Na 
transport near term or at birth (Finley et al., 1998). Because PDE4D5 and PDE4D8 have been 
recently implicated in regulation of beta2-, and beta1-adrenergic signaling in ventricular 
cardiac myocytes (Richter et al., 2008), they might facilitate beta-adrenergic signaling after 
the surge of catecholamines during labor. 
Attempts to localize PDE4D expression within specific cell types in the distal lung did 
not allow assignment of a selective variant to one particular cell type, but demonstrated robust 
expression in alveolar walls on the first day of life. The elongated appearance of staining 
suggested an anchored localization, consistent with a discrete function within alveolar cells. 
Although PDE4D isoforms are more abundant at P1, P3, P7 and P14 than at F20 in whole 
lung homogenates, the signals in the distal lung was faint at P4 and P14, suggesting a main 
site of PDE4D protein expression in the proximal lung and in bronchial tubes. Indeed PDE4D 
has been reported expressed in the smooth muscle of bronchi in adult lungs (Mehats et al., 
2003). Further studies with antibodies directed against selective variants and manipulating 
expression tools in specific pulmonary epithelial and mesenchymal cells will help to decipher 
the role of these PDE4 in developing lungs. 
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In conclusion, the present study identified complex patterns of expression of PDE4s in 
perinatal lung development. We have previously reported impaired alveolarization in rat pups 
chronically treated with rolipram (Mehats et al., 2008), and selective inhibition of discrete 
PDE4 isoforms could prevent this deleterious effect. Further investigations will be designed to 
characterize PDE4s functions. This might provide new therapeutic targets for the prevention 
and care of neonatal respiratory disorders. 
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Materials and methods 
Reagents 
All reagents were from Sigma-Aldrich (L’Isle d’Abeau, France) unless otherwise 
indicated. 
 
Animals and lung tissue sampling 
Time-dated pregnant Sprague-Dawley rats were purchased from Charles River (Saint-
Germain sur l’Arbresle, France). Animal procedures complied with the rules of the Guide for 
Care and Use of Laboratory Animals and were approved by our Institutional Committee on 
Animal Use and Care. Lungs were collected between fetal day 17 and postnatal day 21. Rat 
pups were killed by an intraperitoneal overdose of sodium pentobarbital (70 mg/kg, Ceva, 
Libourne, France). Fetuses were retrieved by cesarean section from pentobarbital-anesthetized 
pregnant females. Lungs were immediately frozen in liquid nitrogen and kept at -80°C until 
RNA extraction or biochemical analyses. For immunofluorescence studies, lungs were gently 
extracted, fixed through a polyethylene tracheal cannula with OCT Tissue Tek (Sakura 
Finetek, Zoeterwoude, The Netherlands) mixed with PBS, and stored at -80°C until frozen 
sections were cut. 
 
RNA isolation and reverse transcription 
Total RNAs were extracted from frozen lung tissue or cell cultures using the RNeasy 
Plus Mini kit
 (Qiagen, Valencia, CA) according to the manufacturer’s instructions. RNAs 
were reverse-transcribed into cDNA using 1µg of total RNA, Superscript III
 
Reverse 
Transcriptase, and oligo-dT primers (Invitrogen, Cergy-Pontoise, France) according to the 
manufacturer’s protocol.  
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PDE4 activity, mRNA expression, protein measurements and localization 
 PDE4 activity 
Lungs were homogenized in ice-cold hypotonic buffer (100 mM Tris-HCl pH 7.4), 2 
mM MgSO4, 2 mM EDTA, 50% glycerol, and 1 mM 2-β-mercaptoethanol supplemented with 
P2714 protease inhibitor cocktail, Sigma) using an all-glass homogenizer. Aliquots of 
homogenates were assayed for cAMP-PDE activity according to the method of Thompson 
and Appleman (Thompson et al., 1974). PDE activities were measured with 1 µM acAMP as 
substrate (GE Healthcare, Amersham, Buckinghamshire, UK). PDE4 activity was defined as 
the fraction of cAMP PDE activity inhibited by 10 µM rolipram. Protein concentrations were 
determined using the protein assay kit from Bio-Rad (Bio-Rad Laboratories, Hercules, CA) 
with BSA as standard. 
 PDE4 mRNA expression level 
Similar amounts of the resulting first-strand cDNA were used as template for real-time 
PCR which was performed by Genoscreen (Lille, France). Primers were designed by 
Genoscreen and the primer sequences are given in Table 1 for the 4 genes and for the specific 
variants studied. Real-time PCR was performed on an ABI Prism 7000 device (Applied 
Biosystems) by Genoscreen. Relative expression was determined using the ΔΔCt (threshold 
cycle) method of normalized samples (ΔCt), in relation to the expression of 18S RNA at F17 
as a calibrator. This calibrator was identical throughout all PCR runs (Livak and Schmittgen, 
2001). 
Measurement of PDE4 proteins by semiquantitative Western blot analysis 
Samples (30 µg protein/lane) were boiled in Laemmli buffer, subjected to 
electrophoresis on 10% SDS-PAGE, and blotted onto Hybond-P transfer membrane (GE 
Healthcare, Amersham). Membranes were blocked in 0.1% Tris Buffered Saline-Tween 20 
containing 5% nonfat milk. Polyclonal rabbit anti-PDE4B antibody (1:2,500) (K118, kindly 
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provided by Prof. Marco Conti (Iona et al., 1998)), and monoclonal mouse anti-PDE4D 
antibody (1:10,000) (61D10E, ICOS Corp., Seattle WA) were used (Bolger et al., 1997). 
Second-step HRP-conjugated antibodies (1:7,000) were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA) and visualized by using ECL detection reagents (GE 
Healthcare Amersham). Labeling with beta-actin antibody (A2066, Sigma; 1:2,000) was used 
as a loading control. Densitometry data for band intensities in different sets of experiments 
was generated by analyzing the gel images on the Image J software (Version 1.33, USA). 
 
PDE4 localization by immunofluorescence and confocal microscopy 
 Lungs fixed and stored as described above were cut into twenty-micrometer-thick 
tissue sections with a Jung CM3000 cryostat (Leica Microsystems GmbH, Wetzlar, 
Germany). Sections were fixed in 4% paraformaldehyde, permeabilized in 0.2% Triton, and 
saturated with 50mM NH4Cl. They were then incubated in 1% PBS-BSA-10% donkey serum 
to block nonspecific binding. The primary antibody, a mouse monoclonal anti-PDE4D 
antibody (M3S1, provided by Prof. Marco Conti (Iona et al., 1998)) diluted to 1:65 in PBS 
was added and incubated overnight at 4°C. The secondary antibody, an Alexa 488-conjugated 
donkey anti-mouse antibody (Molecular Probes, Invitrogen), diluted to 1:200, was added for 1 
h. Sections were also incubated with an anti-pro-SP-C primary antibody (C-19, Santa Cruz 
Biotechnology), diluted to 1:200, then a Rhodamine-conjugated donkey anti-goat secondary 
antibody (TRITC: Jackson ImmunoResearch, Suffolk, UK), diluted to 1:200. After washing in 
PBS, nuclei were counter-stained with TOPRO 3 (Molecular Probes) diluted to 1:1000. 
Normal mouse IgG was used as negative control. Images were recorded on a Leica TCS SP2 
confocal microscope (Leica Microsystems) equipped with a ×63 oil-immersion objective 
(Numerical Aperture=1.32). The three channels were acquired sequentially with the following 
excitation and emission parameters: 488 nm, 500–540 nm for Alexa Fluor 488, 543 nm, 555–
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615 nm for Rhodamine, and 633 nm, 645–750 nm for TOPRO-3. Gains were adjusted to 
avoid saturation pixel intensities. The three channels were color-coded, green, red, and blue, 
and merged. 
 
Statistical analysis 
Values are expressed as mean ± SE, unless otherwise indicated. Multiple comparisons of 
mean values were performed by nonparametric Kruskal-Wallis tests and two-group 
comparisons were performed by a Mann-Whitney U test. A value of p< 0.05 was considered 
to be significant. All calculations were performed with Graph Pad Prism software (San Diego, 
CA, USA). 
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Figure legends 
 
Figure 1. PDE4 activity in homogenates of whole lung from Sprague-Dawley rats at various 
fetal (F) and postnatal (P) ages. Values represent mean ± SD on ten animals per group; 
nonparametric Kruskal-Wallis multiple-group comparison and 2-group comparisons by 
Mann-Whitney U-test. *p<0.05: significantly different from the F17 group; **p<0.05: 
significantly different from the P1 group. 
 
Figure 2. Real-time PCR analysis of PDE4A, PDE4B, PDE4C and PDE4D gene expression 
in developing rat lung at various fetal (F) and postnatal (P) ages. Values represent mean ± SD 
on four animals per group, relative to mRNA levels at F17, arbitrarily set at 1. Note that 
baseline values (see Table 2) are different for each gene. Baseline PDE4C was the lowest 
value, while PDE4D expression was about 64-fold higher and PDE4A and B expression was 
1,000-fold higher. Nonparametric Kruskal-Wallis multiple-group comparison and 2-group 
comparisons by Mann-Whitney U-test: *p<0.05: significant different from the F17 group. 
 
Figure 3. Western blots analysis of PDE4B and PDE4D protein levels in developing rat lung 
at various fetal (F) and postnatal (P) ages. Representative blots obtained with five normal rat 
lungs are shown. Beta-actin signal was used as protein loader control. Densitometric analyses 
of the five blots are plotted below the representative blots. Values represent mean ± SD on 
five animals per group. Nonparametric Kruskal-Wallis multiple-group comparison and 2-
group comparisons by Mann-Whitney U-test: *p<0.05: significant different from the F17 
group. 
 
Figure 4. Real-time PCR analysis of PDE4D long form gene expression in developing rat 
lung at various fetal (F) and postnatal (P) ages. Values represent mean ± SD on four animals 
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per group, relative to mRNA levels at F17, arbitrarily set at 1 Nonparametric Kruskal-Wallis 
multiple-group comparison and 2-group comparisons by Mann-Whitney U-test: *p<0.05: 
significantly different from the F17 group. 
 
Figure 5. Confocal microscopy images of PDE4D in the distal alveolar region of developing 
rat lung at F20. Immunofluorescence was performed using the PDE4D selective antibody 
M3S1 (labeled green, A). Nuclei were counterstained with TOPRO 3 (labeled blue, B). Bar = 
25 µm counterstaining mature type II alveolar epithelial cells, (C) merged image of A and B 
(B). Normal mouse IgG showed no signal (D). Representative panels for staining in two 
normal rat lungs at F20. 
 
Figure 6. Confocal microscopy images of PDE4D in the distal alveolar region of developing 
rat lung at P1. Representative panels for staining in two normal rat lungs, (A) PDE4D 
selective antibody (labeled green), (B) pro-SP-C (labeled red), (C) Nuclei were counterstained 
with TOPRO 3 (labeled blue), (D) merged image. Bar = 37.5 µm. 
 
24 
 
 
Tables 
Table 1- Sequences of primers used in quantitative real-time PCR 
Genes Variants Forward primer Reverse primer 
18S  AAGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 
PDE4A Generic CGTCAGTGCTGCGACAGTC CCAGCGTACTCCGACACACA 
PDE4B Generic GTGGCTGGGTACTCCCATAAT GTCTGGCGTTGCTTCTTGGTA 
 PDE4B2 CCGTCAGTGGCGCCGGGAGC CGAAATGTATTCAGACACTTGGT 
PDE4C Generic CTCAGTCCGGGTCGAGTCT AGGAGCGCCTGCCTAGTG 
PDE4D Generic GCCAGCCTTCGAACTGTAA TCTTGGAATGCAGGAATTGG 
 PDE4D3 GCATGTGAATACCTTCCCTTT TGCACAAAGTTTGCTTGGAG 
 PDE4D4 CACGGAGCGCTACCTGTACT TGCACAAAGTTTGCTTGGAG 
 PDE4D5 TGACCAGGAAAATGGCTCAG CATTGTCCACATCGAAACATGTA 
 PDE4D7 GCCTCTGAGTGGATTACAGTTTC CAGTCGAGTCTGCGGATGT 
 PDE4D8 TGGATCTTAGCCCTCGCTTT TGCACAAAGTTTGCTTGGAG 
 PDE4D9 TATGAAGCCGAGATCCAGGT TGCACAAAGTTTGCTTGGAG 
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Table 2- Analysis of PDE4 gene expression in whole lung tissue at various fetal (F) and 
postnatal (P) ages: mean Delta Ct  
 F17 F19 F21 P1 P7 P14 P21 
PDE4A 11.3±0.8 11.4±1.5 9.4±0.1 9.5±1.4 9.7±1.0 10.1±0.5 10.5±0.3 
PDE4B 11.3±0.6 10.8±0.7 8.0±0.4 6.8±0.8 8.5±1.2 9.0±0.4 10.8±0.4 
PDE4C 21.6±1.3 20.3±1.3 19.2±0.6 18.4±0.7 18.2±1.0 17.0±0.6 15.3±0.3 
PDE4D 14.8±1.0 14.5±0.8 10.9±0.6 9.1±1.3 8.7±1.5 10.8±0.2 12.0±0.4 
        
Isoforms        
PDE4B2 12.6±0.6 11.9±0.9 9.1±0.3 7.9±0.4 9.4±1.2 9.6±0.5 11.5±0.4 
PDE4D3 14.0±1.1 15.2±0.6 12.5±0.2 11.1±0.6 11.9±0.9 12.8±0.1 12.2±0.2 
PDE4D4 15.2±0.0 25.3±2.9 21.6±3.9 17.6±1.8 17.7±3.7 16.7±1.4 18.7±1.1 
PDE4D5 15.1±0.7 16.9±1.4 14.0±0.6 12.1±0.6 13.7±1.2 14.8±0.2 14.8±0.6 
PDE4D7 15.9±0.9 16.1±0.6 11.8±0.4 11.4±0.2 11.7±1.4 12.3±0.7 11.9±0.6 
PDE4D8 13.7±0.3 13.2±0.6 10.7±0.3 10.1±0.7 10.9±0.7 11.6±0.3 11.4±0.3 
PDE4D9 11.5±0.6 11.9±0.5 10.6±0.7 9.1±0.8 9.4±0.8 10.1±0.4 10.5±0.2 
 
Data are presented as mean ± SEM of data obtained from at least three animals at each age. 
Delta Ct was calculated by subtracting Sample Ct to 18S Ct of matching age. Note: a decrease 
in the Delta Ct value represents an increase in mRNA expression and a variation of 1 cycle 
means a two-fold increase or a decrease. 
 
